FindTrial
Sign In

PD:26

2 trials

Sponsors

GlaxoSmithKline Biologicals

Conditions

Two doses vaccination in adults subjects aged between 18 and 40 years old, in good general health and not previously immunized with the 23-valent pneumococcal polysaccharide vaccine.Two doses vaccination in elderly subjects aged between 65 and 85 years old, in good general health and not previously immunized with the 23-valent pneumococcal polysaccharide vaccine (Pneumo 23).

Phase 1

An open, phase I/II study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ 11PCV combined with adjuvant AS02V given as a 2-dose vaccination in adults aged 18-40 years old. - EXPLO-CRD-006
Active, not recruitingEUCTR2006-000442-39-BE
GlaxoSmithKline BiologicalsTwo doses vaccination in adults subjects aged between 18 and 40 years old, in good general health and not previously immunized with the 23-valent pneumococcal polysaccharide vaccine.
Start: 2006-04-12Target: 10Updated: 2022-03-28

Unknown Phase

A phase I/II, randomized, observer blinded study to evaluate and compare the safety, reactogenicity and immunogenicity of various formulations of the GlaxoSmithKline Biologicals’ adjuvanted 11-valent pneumococcal conjugate vaccine versus the licensed single-dose 23-valent pneumococcal polysaccharide vaccine and GlaxoSmithKline Biologicals’ aluminium-based 10-valent pneumococcal conjugate vaccine, in healthy elderly subjects. - STREP-ELD-010, STREP-ELD-011 EXT010 Y1
Active, not recruitingEUCTR2005-005682-11-SE
GlaxoSmithKline BiologicalsTwo doses vaccination in elderly subjects aged between 65 and 85 years old, in good general health and not previously immunized with the 23-valent pneumococcal polysaccharide vaccine (Pneumo 23).
Start: 2006-04-24Target: 330Updated: 2012-03-19